Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.
People
Related News
July 28, 2025
In the News
Mark Wolfson Honored in Florida Bar Spotlight
Foley & Lardner LLP partner Mark Wolfson was featured by The Florida Bar for his contributions to the Florida legal community in a "Past Chair Spotlight."
July 24, 2025
In the News
Margaret Nelson Assesses SEC Enforcement Philosophy
Foley & Lardner LLP partner Margaret Gembala Nelson commented in the Private Equity Law Report article, "SEC Enforcement Action Raises Potential Materiality Threshold for Conflicts of Interest," sharing insight on enforcement philosophy at the U.S. Securities and Exchange Commission.
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."